CD34 and Sepsis: In the perspective of potential therapeutic strategies with EPCs in combination with SDF-1α analogue, which have been successfully administered in septic animal models, our findings represent a compelling reason to further study the kinetics of CD133+/CD34+ expressing stable HIF-1α and their linkage to SDF-1α in human sepsis [35].